Citations

Clear

16281 citation(s) found for "Yu, David".

Flavonoid Apigenin Is an Inhibitor of the NAD+ase CD38
Escande, Carlos , Nin, Verónica , Price, Nathan L. , Capellini, Verena Kise , Gomes, Ana P., Barbosa, Maria Thereza , O’Neil, Luke, White, Thomas A. , Sinclair, David , Chini, Eduardo N. , Sinclair, David A

Mayo Clinic

Diabetes | November 20, 2012 | Volume: 62 | Issue: 4 | Pages: 1084-1093

10.2337/db12-1139 | PMID 23172919 Get It

Metabolic syndrome is a growing health problem worldwide. It is therefore imperative to develop new strategies to treat this pathology. In the past years, the manipulation of NAD+ metabolism has emerged as a plausible strategy to ameliorate metabolic syndrome. In particular, an increase in cellular NAD+ levels has beneficial effects, likely because of the activation of sirtuins. Previously, we reported that CD38 is the primary NAD+ase in mammals. Moreover, CD38 knockout mice have higher NAD+ levels and are protected against obesity and metabolic syndrome. Here, we show that CD38 regulates global protein acetylation through changes in NAD+ levels and sirtuin activity. In addition, we characterize two CD38 inhibitors: quercetin and apigenin. We show that pharmacological inhibition of CD38 results in higher intracellular NAD+ levels and that treatment of cell cultures with apigenin decreases global acetylation as well as the acetylation of p53 and RelA-p65. Finally, apigenin administration to obese mice increases NAD+ levels, decreases global protein acetylation, and improves several aspects of glucose and lipid homeostasis. Our results show that CD38 is a novel pharmacological target to treat metabolic diseases via NAD+-dependent pathways.
Outcome Following Aminosalicylate Therapy in Children Newly Diagnosed As Having Ulcerative Colitis
Zeisler, Bella, Lerer, Trudy, Markowitz, James , Mack, David , Bousvaros, Athos, Keljo, David J., Rosh, Joel R. , Evans, Jonathan, Otley, Anthony , Kay, Marsha , Grossman, Andrew B., Saeed, Shehzad A. , Carvalho, Ryan , Oliva‐Hemker, Maria , Faubion, William A. , Sudel, Boris , Pfefferkorn, Marian, Ashai-Khan, Farhat N., LeLeiko, Neal S. , Hyams, Jeffrey S. , Griffiths, Anne Marie , Kappelman, Michael D. , Leleiko, Neal S

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | November 17, 2012 | Volume: 56 | Issue: 1 | Pages: 12-18

10.1097/mpg.0b013e31826ac41a | PMID 22847466 Get It

ABSTRACTObjectives:Despite a paucity of published supporting data, 5‐aminosalicylate (5‐ASA) use in pediatric ulcerative colitis (UC) is common. The present study describes the use and outcome of a large multicenter inception cohort of children with UC treated with 5‐ASA.Methods:Data were obtained from the Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry, a prospective North American observational study of children newly diagnosed as having inflammatory bowel disease ages 16 years or younger. Patient data are recorded at diagnosis, 30 days, and then quarterly. Patients are managed by physician dictate, not protocol. Disease activity is classified by physician global assessment. The primary outcome examined was corticosteroid (CS) free, inactive UC at 1 year following initiation of 5‐ASA within 30 days of diagnosis (with or without concomitant CS use) without the need for rescue therapy (immunomodulators, biologics, or colectomy).Results:Study subjects included 213 patients newly diagnosed as having UC who received oral 5‐ASA compounds (115 of whom also received CS) during the first 30 days after diagnosis, and no other oral therapies for the treatment of UC. Of these 213 patients, 86 (40%) were CS free and physician global assessment inactive at 1 year without rescue. Outcome was not associated with disease severity at diagnosis, demographic or laboratory factors examined, or initial dose of 5‐ASA used.Conclusions:Forty percent of children taking 5‐ASA as primary maintenance therapy at diagnosis are in CS‐free remission after 1 year of treatment. Further pediatric studies will be needed to address whether increased adherence and/or higher dosing schedules will improve outcomes.
Self-Report of Child Care Directors Regarding Return-to-Care
Hashikawa, Andrew N. , Stevens, Martha W., Juhn, Young J. , Nimmer, Mark, Copeland, Kristen A. , Simpson, Pippa , Brousseau, David C.

Mayo Clinic

Pediatrics | November 13, 2012 | Volume: 130 | Issue: 6 | Pages: 1046-1052

10.1542/peds.2012-1184 | PMID 23147967 Get It

BACKGROUND:The American Academy of Pediatrics (AAP) introduced revised return-to-care recommendations for mildly ill children in 2009 that were added to national standards in 2011. Child care directors' practices in a state without clear emphasis on return-to-care guidelines are unknown. We investigated director return-to-care practices just before the release of recently revised AAP guidelines.METHODS:A telephone survey with 5 vignettes of mild illness (cold symptoms, conjunctivitis, vomiting/diarrhea, fever, and ringworm) was administered to randomly sampled directors in metropolitan Milwaukee, Wisconsin. Directors were asked about return-to-care criteria for each illness. Questions for return-to-care criteria were open-ended; multiple responses were allowed. Answers were compared with AAP return-to-care recommendations.RESULTS:A total of 305 directors participated. Based on director responses to vignettes, the percentage of correct responses regarding return-to-child care management compared with AAP return-to-care recommendations was low: fever (0%); conjunctivitis (0%); diarrhea (1.6%); cold symptoms (12%); ringworm (21%); and vomiting (80%). Two illnesses (conjunctivitis and cold symptoms) would require the child to have an urgent medical evaluation or treatment not recommended by the AAP, as follows: Conjunctivitis—antibiotics for 24 hours (62%), physician visit (49%), any antibiotic treatment (6%), and symptom resolution (4%); and Cold Symptoms—physician visit (45.6%), antibiotics (10%), and symptom resolution (25%).CONCLUSIONS:Directors’ self-reported return-to-child care practices differed substantially before the release of revised AAP return-to-care recommendations. Active adoption of AAP return-to-child care guidelines would decrease the need for unnecessary urgent medical evaluation and treatment as well as unnecessary exclusion of a child from child care.
Correlates of Moderate-to-Vigorous Physical Activity Participation in Adults With Intellectual Disabilities
Bodde, Amy E. , Seo, Dong‐Chul , Frey, Georgia C. , Puymbroeck, Marieke Van , Lohrmann, David K.

Mayo Clinic

Health Promotion Practice | November 10, 2012 | Volume: 14 | Issue: 5 | Pages: 663-670

10.1177/1524839912462395 | PMID 23142762 Get It

Adults with intellectual disabilities (ID) have low levels of physical activity and higher than average rates of related chronic health conditions. Understanding correlates of their physical activity participation may improve health promoting interventions. Forty-two adults with ID participated in a physical activity study. Physical activity knowledge and skills, awareness of recommendations and demographic characteristics were analyzed for their association with moderate-to-vigorous physical activity (MVPA) participation measured by accelerometers. Five variables were significantly correlated with MVPA. Body mass index was inversely correlated with MVPA, and gender, job location, job tasks, and place of residence were all significantly associated with MVPA. Understanding correlates of physical activity in this population will help inform disability service and health promotion professionals in future research and health intervention design.
Faculty Opinions recommendation of Hand-sewn versus mechanical esophagogastric anastomosis after esophagectomy: a systematic review and meta-analysis.
Katzka, David A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 9, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717958755.793464390 Get It

Faculty Opinions recommendation of Meta-analysis: oral bisphosphonates and the risk of oesophageal cancer.
Katzka, David A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 9, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717958540.793464389 Get It

Faculty Opinions recommendation of Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial.
Katzka, David A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 9, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717958732.793464387 Get It

PATIENT SELF-ASSESSMENT FACTORS PREDICTIVE OF PERSISTENT DEPRESSIVE SYMPTOMS 6 MONTHS AFTER ENROLLMENT IN COLLABORATIVE CARE MANAGEMENT
Angstman, Kurt B. , Shippee, Nathan D. , MacLaughlin, Kathy L. , Rasmussen, Norman H., Wilkinson, John M. , Williams, Mark D. , Katzelnick, David J., Shippee, Nathan

Mayo Clinic

Depression and Anxiety | November 8, 2012 | Volume: 30 | Issue: 2 | Pages: 143-148

10.1002/da.22020 | PMID 23139162 Get It

Human MCS5A1 candidate breast cancer susceptibility gene FBXO10 is induced by cellular stress and correlated with lens epithelium-derived growth factor (LEDGF)
Xu, Xin , Powell, David W. , Lambring, Courtney J., Puckett, Aaron H., Deschenes, Lucas , Prough, Russell A. , Poeschla, Eric M. , Samuelson, David J.

Mayo Clinic

Molecular Carcinogenesis | November 8, 2012 | Volume: 53 | Issue: 4 | Pages: 300-313

10.1002/mc.21977 | PMID 23138933 Get It

An allergic phenotype and the use of steroid inhalers predict eosinophilic oesophagitis in patients with asthma
Harer, Kimberly, Enders, Felicity , Lim, Kaiser G. , Alexander, Jeffrey A. , Katzka, David A. , Enders, Felicity T , Lim, Kaiser G

Mayo Clinic

Alimentary Pharmacology & Therapeutics | November 8, 2012 | Volume: 37 | Issue: 1 | Pages: 107-113

10.1111/apt.12131 | PMID 23134444 Get It

SummaryBackgroundPatients with eosinophilic oesophagitis (EoE) commonly have asthma and atopy.AimsTo determine the predictive factors of EoE in patients with asthma.MethodsA retrospective analysis of a large database identified 156 asthma patients with EoE and 276 patients without EoE between 2000 and 2010. Clinical and laboratory characteristics were first analyzed in half of each group. Significant differences and modelling were then applied to the other half of each group in a split half analysis.ResultsOdds ratios and P‐values found to predict the presence of EoE in asthma patients were: allergic vs. non‐allergic asthma (4.07, <0.01), food allergies (45, <0.01), allergic rhinitis (2.13, =0.01) and peripheral eosinophilia (4.51, <0.01). The use of inhaled corticosteroids was negatively associated with EoE (0.41, <0.01) for asthma patients and (0.37, P < 0.01) for allergic type asthma patients. EoE patients were also younger (27.4 vs. 41.6 years old, P < 0.01). By logistic regression analysis, allergic asthma, presence of peripheral eosinophilia and use of inhaled steroids remained significant. From these parameters, a 3.5‐point scoring system model for EoE in asthma was formed with an ROC = 0.787 on split analysis.ConclusionsIn descending order, peripheral eosinophilia, allergic asthma and allergic rhinitis are associated with EoE in patients with asthma. Steroid inhalers appear to have a protective effect against EoE. An accurate and simple scoring system can be used as a screening tool to predict the presence of EoE in patients with asthma and dysphagia. EoE should be viewed as part of a generalised allergic phenotype rather than isolated oesophageal disease.